Evidence map›Paper›PMID 40894137›Full record

ArticlemedRxiv : the preprint server for health sciences2025

A Phase 0 Window of Opportunity Trial of LB100, a Protein Phosphatase 2A Inhibitor, in Patients with Recurrent Gliomas.

Eric C Burton, Erin Walker, Lisa Boris, Jennifer Reyes, Kelly Fernandez, Kathleen Wall, Jing Wu, Keith T Schmidt, William D Figg, Desmond A Brown

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Eric C BurtonNeuro-oncology Branch, National Cancer Institutes, 9030 Old Georgetown Road, Building 82, Bethesda, MD 20892.
Erin WalkerNeurosurgical Oncology Unit, Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892-1414.
Lisa BorisNeuro-oncology Branch, National Cancer Institutes, 9030 Old Georgetown Road, Building 82, Bethesda, MD 20892.
Jennifer ReyesNeuro-oncology Branch, National Cancer Institutes, 9030 Old Georgetown Road, Building 82, Bethesda, MD 20892.
Kelly FernandezNeuro-oncology Branch, National Cancer Institutes, 9030 Old Georgetown Road, Building 82, Bethesda, MD 20892.
Kathleen WallNeuro-oncology Branch, National Cancer Institutes, 9030 Old Georgetown Road, Building 82, Bethesda, MD 20892.
Jing WuNeuro-oncology Branch, National Cancer Institutes, 9030 Old Georgetown Road, Building 82, Bethesda, MD 20892.
Keith T SchmidtCenter for Cancer Research, National Cancer Institute, National Institutes of Health, Besthesda, MD 20892.
William D FiggCenter for Cancer Research, National Cancer Institute, National Institutes of Health, Besthesda, MD 20892.ORCID 0000-0003-2428-5613
Desmond A BrownNeurosurgical Oncology Unit, Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892-1414.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: LB100 is a protein phosphatase 2A (PP2A) inhibitor. Glioma models show inhibition of PP2A by LB100 causes cell death. Whether LB100 crosses the human blood brain barrier (BBB) is unknown. We sought to determine the pharmacokinetic (PK) properties of LB100 in human subject gliomas. Methods: A two-stage, phase 0 trial was done. Eligibility required a recurrent adult diffuse type of glioma deemed surgically resectable. In the first stage, 5 patients were pre-surgically dosed with LB100. Resected tumor then underwent PK analysis by LC-MS/MS. If one of five tumors demonstrated a PK response three additional subjects would be enrolled. Pharmacokinetic effect would be declared significant if at least 2 of 8 patients demonstrated a PK response and pharmacodynamic studies would then be performed. Results: Five patients were evaluable. Glioblastoma, (n=2), Astrocytoma IDH-mutant grade 3- 4 (n=2), and Oligodendroglioma IDH-mutant, grade 2 (n=1). Mean C Conclusion: In this first PK analysis of LB100 in human gliomas there was poor penetration of LB100 into glial tumors.

Identifiers

PMID40894137
PMCPMC12393660

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.